Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “VACCINEX, INC.”

41 pharma patents match "VACCINEX, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 41
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 41 pharmaceutical patents matching "VACCINEX, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

41 results for “VACCINEX, INC.” · 30,257 patents in full index Clear search

  1. US 9676840

    Anti-CD100 neutralizing antibodies and methods of using the same

    VACCINEX, INC. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted
  2. US 9603922

    Modulation of NKT cell activity with antigen-loaded CD1d molecules

    VACCINEX, INC. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  3. US 9605055

    Anti-CD100 antibodies and methods of using the same

    VACCINEX, INC. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  4. US 9598495

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    VACCINEX, INC. · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted
  5. US 9512224

    Use of semaphorin-4D binding molecules for treatment of atherosclerosis

    VACCINEX, INC. · Granted Dec 6, 2016 · Expires Dec 1, 2036

    granted
  6. US 9382327

    Anti-CD20 antibodies and methods of use

    VACCINEX, INC. · Granted Jul 5, 2016 · Expires Jun 30, 2036

    granted
  7. US 9371352

    Modified glycolipids and methods of making and using the same

    VACCINEX, INC. · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted
  8. US 9249227

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    VACCINEX, INC. · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted
  9. US 9243068

    Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

    VACCINEX, INC. · Granted Jan 26, 2016 · Expires Jan 21, 2036

    granted
  10. US 8834883

    Anti-VEGF antibodies and uses thereof

    VACCINEX, INC. · Granted Sep 16, 2014 · Expires Sep 11, 2034

    granted
  11. US 8816058

    Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof

    VACCINEX, INC. · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted
  12. US 8790652

    Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis

    VACCINEX, INC. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted
  13. US 8637026

    Anti-C35 antibody combination therapies and methods

    VACCINEX, INC. · Granted Jan 28, 2014 · Expires Jan 23, 2034

    granted
  14. US 8496938

    Anti-CD100 neutralizing neutralizing antibodies and methods of using the same

    VACCINEX, INC. · Granted Jul 30, 2013 · Expires Jul 25, 2033

    granted
  15. US 7919594

    Human anti-CD100 antibodies

    VACCINEX, INC. · Granted Apr 5, 2011 · Expires Mar 31, 2031

    granted
  16. US 7919095

    Anti-IL-6 monoclonal antibodies

    VACCINEX, INC. · Granted Apr 5, 2011 · Expires Mar 31, 2031

    granted
  17. US 7807168

    Selection of human TNFα specific antibodies

    VACCINEX, INC. · Granted Oct 5, 2010 · Expires Sep 30, 2030

    granted